Galera Therapeutics Stock News

HC Wainwright upgraded shares of Galera Therapeutics (NASDAQ:GRTX) from a neutral rating to a buy rating in a research report report published on Wednesday morning, Price Targets.com reports. They currently have $10.00 price target on the stock. Other research analysts have also issued reports about the stock. Zacks Investment Research raised shares of Galera Therapeutics []

Galera Therapeutics (NASDAQ:GRTX) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research report issued to clients and investors on Thursday, Zacks.com reports. According to Zacks, Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel, proprietary therapeutics to transform radiotherapy in [] The post Galera Therapeutics (NASDAQ:GRTX) Lowered to Hold at Zacks Investment Research appeared first on ETF Daily News .

Galera Therapeutics, Inc. (NASDAQ:GRTX) with the stream of -3.79% also noticed, India Enbridge Inc. (NYSE:ENB) encountered a rapid change of 0.73% in the last hour of Thursdays trading session. Galera The post Analysts Suggestions in the Limelight: Galera Therapeutics, Inc. (NASDAQ:GRTX), Enbridge Inc. (NYSE:ENB) appeared first on Stocks Equity .

Galera Therapeutics (NASDAQ:GRTX) was upgraded by equities researchers at Bank of America from an underperform rating to a neutral rating in a research report issued on Tuesday, The Fly reports. Several other brokerages have also commented on GRTX. Citigroup dropped their price target on shares of Galera Therapeutics from $21.00 to $11.00 and set a []

Gainers Nxt-ID, Inc. (NASDAQ: NXTD ) shares gained 28.9% to $3.21 after the company said it was awarded U.S. General Services Administration contract to distribute personal emergency response systems to Federal, State and Local government purchasers. Biofrontera Inc. (NASDAQ: BFRI ) shares climbed 27.6% to $7.02 after Benchmark initiated coverage on the stock with a Buy rating and announced a $11 price target. CMC Materials, Inc. (NASDAQ: CCMP ) surged 25.9% to $183.74 after the company announced it will be acquired by Entegris for $6.5 billion in cash and stock. Insignia Systems, Inc. (NASDAQ: ISIG ) surged 21.2% to $20.18. Gemini Therapeutics, Inc. (NASDAQ: GMTX ) gained 21% to $2.94 after HC Wainwright & Co initiated coverage on the stock with a Buy rating and a $20 price target. mCloud Technologies Corp. (NASDAQ: MCLD ) jumped 17.2% to $4.6405 after the company signed a cloud agreement with Virtual Vision to host AssetCare customers in Saudi Arabia. Vir Biotechnology, Inc. (NASDAQ: VIR ) gained 15.2% to $53.03 after the company announced new preclinical data demonstrating the impact of the significant antigenic shift of the new SARS-CoV-2 Omicron variant.

Investors need to pay close attention to Galera (GRTX) stock based on the movements in the options market lately.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Galera Therapeutics (GRTX) stock is rocketing higher on Tuesday after the company revealed corrected results from a Phase 3 clinical trial. The post GRTX Stock Alert: The Surprising News That Has Galera Therapeutics Going Gangbusters Today appeared first on InvestorPlace . More From InvestorPlace Stock Prodigy Who Found NIO at $2 Says Buy THIS Now Man Who Called Black Monday: Prepare Now. #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First

Galera Therapeutics Inc (NASDAQ: GRTX ) has announced corrected results from its Phase 3 ROMAN trial of avasopasem for RT-induced severe oral mucositis (SOM) in patients with locally advanced head and neck cancer (HNC). The corrected data showed that avasopasem achieved statistical significance on the primary endpoint of reduction in the incidence of SOM. Previously it announced that the trial did not … Full story available on Benzinga.com

NEW YORK , Dec. 14, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GRTX, TMX, AGLE, ALZN, and SELB. … Full story available on Benzinga.com

Wondering how to trade penny stocks and which could be worth watching? The post Penny Stocks Are Volatile, Here's How to Trade Them and 3 to Watch appeared first on Penny Stocks to Buy, Picks, News an

Corrected topline Phase 3 ROMAN data demonstrate primary endpoint achieved statistical significance in reducing the incidence of radiotherapy-induced severe oral mucositis (p=0.045) Topline results from single-arm Phase 2a trial of avasopasem in Europe in line with the ROMAN trial results Company plans to discuss avasopasem data with the FDA in 2022 Company to host conference call and live audio webcast on Tuesday, December 14 at 8:30 a.m. ET MALVERN, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ: GRTX ), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy (RT) in cancer, today announced that corrected results from its Phase 3 ROMAN trial of avasopasem for the treatment of RT-induced severe oral mucositis (SOM) in patients with locally advanced head and neck cancer (HNC) achieved statistical significance on the primary endpoint of reduction in the incidence of SOM.

Galera Therapeutics (GRTX) stock is rocketing higher on Tuesday after the company revealed corrected results from a Phase 3 clinical trial. The post GRTX Stock Alert: The Surprising News That Has Gale

The stock price of Galera Therapeutics Inc (NASDAQ: GRTX) increased by over 118% pre-market today. This is why it happened.

Zacks Investment Research cut shares of Galera Therapeutics (NASDAQ:GRTX) from a buy rating to a hold rating in a research report report published on Friday, Zacks.com reports. According to Zacks, Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel, proprietary therapeutics to transform radiotherapy in cancer. The companys []